Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02675400 · ClinicalTrials.gov registry record · Phase 4
Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)
A Phase 4 study, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT02675400: Completed Phase 4 study, sponsored by Seattle Children's Hospital.
NCT02675400 is a Phase 4 study that has completed, run by Seattle Children's Hospital. The registered enrollment target is 19 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02675400, a Phase 4 study, has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
In contrast to mothers with Attention Deficit/Hyperactivity Disorder (ADHD), the impact of paternal ADHD in families and children with ADHD symptoms has not been studied, despite the prevalence of ADHD in males. Thus, the investigators do not know the feasibility, impact on treatment on the family and child, and effects of treating fathers relative to mothers with ADHD. Paternal ADHD is associated with negative parenting and child conduct problems. The investigators hypothesize that successfully treating parental ADHD in fathers will have a beneficial effects on the family that will extend to the child. Specifically, the investigators believe that stimulant medication ((Lisdexamfetamine (LDX) or a different ADHD medication if poor response to LDX) with fathers will reduce father's ADHD symptoms and improve parenting. Effects of stimulant treatment of fathers will be compared to Behavioral Parent Training (BPT) on parenting, and paternal and child outcomes in fathers with ADHD who have children between the ages of 3 -8. As in the investigator's previous work, the investigators will bank paternal and child DNA and RNA for later examination of pharmacogenetic and epigenetic effects (i.e. RNA) of stimulant response.
Primary Outcome
Clinical Global Impression - Severity .
Interventions
- DRUG Methylphenidate
- BEHAVIORAL Behavioral Parent Training
- DRUG Vyvanse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-08-31 |
| Phase | Phase 4 |
What the finished NCT02675400 record still lists
NCT02675400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 3 interventions - of which Methylphenidate is the first listed.
NCT02675400 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02675400 about?
NCT02675400 is a clinical study titled "Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)". In contrast to mothers with Attention Deficit/Hyperactivity Disorder (ADHD), the impact of paternal ADHD in families and children with ADHD symptoms has not been studied, despite the prevalence of ADHD in males. Thus, the investigators do not know the feasibility, impact on treatment on the family a...
What is the current status of trial NCT02675400?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2015-12. Estimated completion is 2018-08-31.
What interventions are being tested in trial NCT02675400?
The interventions under investigation include: Methylphenidate (DRUG), Behavioral Parent Training (BEHAVIORAL), Vyvanse (DRUG).
Who is sponsoring clinical trial NCT02675400?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02675400's enrollment target sits among peer trials
19 1834th of 2000 higher than 159 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia